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UNIT 4.3Direct Attachment of Conjugate Groups to
the 5′ Terminus of Oligodeoxyribonucleotides
The attachment of conjugate groups (intercalating and photoreactive groups) to the 5′
terminus of oligodeoxyribonucleotides can be achieved using either of two strategies.
This unit presents one strategy, the direct incorporation of ligands during oligodeoxyri-
bonucleotide synthesis using phosphoramidite derivatives. The second strategy, coupling
of an unblocked oligomer with a ligand via a specific reaction between the reactive groups
present in both entities, will be presented in future units. The protocols delineated below
cover the direct addition of an intercalator, 2-methoxy-6-chloro-9-aminoacridine (see
Basic Protocol 1), and a photo-cross-linking reagent, psoralen (see Basic Protocol 2), to
the 5′ end of oligonucleotides via their phosphoramidite derivatives. These procedures
require the following steps: the incorporation of hydroxylated linkers into ligands, the
preparation of the phosphoramidite derivatives, and the addition of the latter to the 5 ′ ends
of protected oligonucleotides bound to the support. After deprotection, the oligodeoxyri-
bonucleotide conjugates are purified and characterized (see Support Protocol). Properties
of a number of conjugates synthesized by these procedures are discussed in UNIT 4.2.
CAUTION: All chemicals must be handled in a fume hood by individuals equipped with
lab coats, glasses, and gloves.
BASIC
PROTOCOL 1
DIRECT ADDITION OF ACRIDINE DERIVATIVES TO THE 5′ END OF
OLIGODEOXYRIBONUCLEOTIDES
This strategy (illustrated in Figs. 4.3.1, 4.3.2, and 4.3.3) involves the covalent attachment
of a linker carrying a hydroxyl function to the acridine derivative S.1b, and the preparation
of the acridinyl phosphoramidite derivative S.1c. The acridinyl phosphoramidite deriva-
tive can be coupled either automatically or manually to the 5′-terminal hydroxyl group
of oligodeoxyribonucleotides bound to solid supports. After deprotection, the acridine-
oligodeoxyribonucleotide conjugate S.1d is purified and characterized as described in the
Support Protocol.
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Figure 4.3.1 Synthesis of acridine and psoralen derivatives functionalized with hydroxylated
linkers.
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Figure 4.3.2 Synthesis of the phosphoramidite derivatives of acridine and psoralen ligands.
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Figure 4.3.3 Direct addition of ligands to the 5′ terminus of oligodeoxyribonucleotides.
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Materials
6-Amino-1-hexanol
6,9-Dichloro-2-methoxyacridine
Phenol
Dichloromethane (CH2Cl2), distilled from P2O5 and passed over activated, basic
aluminum oxide
Distilled methanol (MeOH)
2 M sodium hydroxide (NaOH)
Acetonitrile (CH3CN), HPLC grade
2,6-Dibromo-4-benzoquinone-N-chloroimine (DBPNC; Prolabo)
Ethanol, distilled
P2O5
Acetonitrile (CH3CN), DNA synthesis grade, anhydrous and stored over 3-Å
molecular sieves
N,N-Diisopropylethylamine (DIEA), distilled from KOH
2-Cyanoethyl-N,N-diisopropylchlorophosphite
Ethyl acetate, distilled
Hexane, distilled
Triethylamine (Et3N), distilled from KOH
10% (w/v) Na2CO3
Saturated NaCl (brine)
MgSO4
Oligodeoxyribonucleotide bound to solid supports, such as controlled-pore glass
(CPG; UNIT 3.1), synthesized by classic phosphoramidite chemistry (1-µmol
scale; UNIT 3.3 and APPENDIX 3C)
DNA synthesis reagents recommended by the synthesizer’s manufacturer
0.4 M sodium hydroxide (NaOH) in 50:50 (v/v) MeOH/H2O
Dowex 50 resin, pyridinium form (Aldrich)
Round-bottomed flasks (various sizes) with rubber septa and glass stoppers
Drying tube containing CaCl2
Reflux condenser
Analytical thin-layer chromatography (TLC) setup and silica-gel plates: e.g.,
Merck 5554 Kieselgel 60F plates, including UV lamp for detection
Desiccator
Beakers, various sizes
Silica gel for column chromatography: Merck 9387 Kieselgel 60 or Merck 7734
Kieselgel 60
Chromatographic column (3 cm × 45 cm)
Argon
Nitrogen gas
Spectrophotometer
Rotary evaporator with water bath
Chemically inert syringes with replaceable needles
Funnel
Separatory funnels (various sizes)
Filter (porosity 4)
Vials and Teflon-faced septa
Disposable filters for syringes and for filtration of HPLC buffers
Liquid chromatography apparatus equipped with multiwavelength detector
Melting-point apparatus
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Synthesize 2-methoxy-6-chloro-9-(ω-hydroxyhexylamino)-acridine S.1b
1. Place 840 mg (7.18 mmol) 6-amino-1-hexanol, 1 g (3.59 mmol) 6,9-dichloro-2-
methoxyacridine, and 2.5 g phenol in a 25-mL round-bottomed flask equipped with
a magnetic stir-bar, a reflux condenser, and a calcium chloride drying tube. Heat 80
to 90 min at 100°C.
2. Perform TLC analysis on a silica-gel plate using 90:10 (v/v) CH2Cl2/MeOH as the
eluent to check that the reaction is complete. Dilute an aliquot 10-fold with MeOH
and load 1 µl on the TLC plate.
This should show the disappearance of 6,9-dichloro-2-methoxyacridine (Rf = 0.9) and theformation of a new compound (Rf = 0.18).
3. Allow the mixture to cool, dilute it with 2.5 mL MeOH, and add the solution dropwise
to a magnetically stirred 2 M NaOH solution (20 mL contained in a 100-mL beaker).
Maintain stirring for 15 min.
4. Filter the yellow precipitate using a porosity 4 filter and wash it with water until
neutral. Crystallize twice from 20:80 (v/v) H2O/MeOH.
Expected yield: 80% (1.03 g, 2.87 mmol).
5. Analyze the product by TLC using silica-gel plates and 75:25 (v/v) CH2Cl2/MeOH
as eluent. Dilute 1 to 2 mg in 100 µl MeOH and use 1 µl for spotting. 
In addition to 2-methoxy-6-chloro-9-(-hydroxyhexylamino)-acridine (S.1b,  Rf =
0.58),TLC analysis will show three side products, identified as the starting material
6,9-dichloro-2-methoxyacridine (Rf = 0.85), 2-methoxy-6-chloro-9-acridone (Rf = 0.81),
and an unidentified third product (Rf = 0.39). These three products do not react during
subsequent steps and are easily removed from the conjugates during purification. 
Reversed-phase HPLC as reported in Asseline et al., 1986 can also be used.
Purity should be ∼95%.
Characterize the product by other analytical methods as desired. Melting point: 152° to
153°C.
1H-NMR (DMSO-d6): δ 1.15-1.40 (m, 6H, CH2CH2CH2), 1.60-1.75 (m, 2H, CH2), 3.20-
3.33 (m, 3H, CH2N + NH), 3.61-3.75 (m, 2H, CH2OH), 3.90 (s, 3H, OCH3), 4.20-4.28, (m,
1H), 7.25-7.88 (m, 5H, Acr), 8.25-8.38 (m, 1H, H8 Acr).
Mass analysis: I.S. Polarity positive. Calculated for C20H23ClN2O2: M+H= 359.18 and
361.18. Found 359.5 and 361.5.
6. Check for the absence of sodium phenolate by TLC analysis using the conditions
described in step 5. Place plate in fume hood and dry using a hair dryer. Spray the
TLC plate with a solution of 50 mg 2,6-dibromo-4-benzoquinone-N-chloroimine
(DBPNC) in 20 mL ethanol and heat with a TLC drying plate or in an oven at
100°–130°C for several minutes.
Phenol will give a blue-colored spot.
Prepare [2-methoxy-6-chloro-9-(ω-hexylamino)-acridinyl]-(2-cyanoethyl)-N,N-diiso-
propyl-phosphoramidite, S.1c
7. Place 300 mg (0.83 mmol) 2-methoxy-6-chloro-9-(ω-hydroxyhexylamino)acridine,
S.1b, in a 25-mL round-bottomed flask and dry it by three rounds of coevaporation
with anhydrous acetonitrile (3 × 5 mL).
8. Place a stir bar in the flask and stopper it with a septum. Push a needle through the
septum and leave the flask in a P2O5-containing desiccator under vacuum overnight.
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9. Fill the desiccator with nitrogen before opening it.
10. Under argon atmosphere and magnetic stirring, add with a syringe 6 mL anhydrous
CH3CN, 0.32 mL DIEA (235 mg, 1.82 mmol), and 0.2 mL 2-cyanoethyl-N,N-diiso-
propylchlorophosphite (216 mg, 0.91 mmol) at room temperature.
11. Let reaction proceed 30 min. Monitor its progress by TLC on a silica-gel plate using
50:50:4 (v/v/v) ethyl acetate:hexane:Et3N as eluent. Pre-elute the TLC plate once
with the eluent, then load 1 µl of the reaction mixture and elute.
After 30 min the starting material S.1b (Rf = 0.10) is transformed into two new compounds,
a main product (≈80%; Rf = 0.50) and a side-product (≈15%; Rf = 0.65). Trace amounts
of the starting material are also observed.
12. Add 20 mL CH2Cl2 and wash the organic layer with 3 mL of 10% (w/v) aqueous
Na2CO3 and then 3 mL of saturated NaCl (brine). Decant the organic phase, dry it
over MgSO4, and concentrate it to dryness.
13. Apply the residue, diluted with 2 to 3 mL anhydrous CH3CN to a silica-gel chroma-
tography column (3 cm × 45 cm, containing 60 g silica gel) and elute with 500 mL
of 50:50:4 (v/v/v) ethyl acetate:hexane:Et3N. Monitor the fractions by TLC analysis
using 50:50:4 (v/v/v) ethyl acetate:hexane:Et3N as eluent, and collect the main
product (Rf = 0.50). 
14. Pool the fractions containing the pure product, and remove the solvent under reduced
pressure. Coevaporate the residue twice using 8 mL anhydrous CH3CN each time.
Expected yield: 65% (300 mg, 0.54 mmol) of a yellow oil. Purified acridinyl phos-
phoramidite S.1c can be stored at −20°C for a few months and should be reconstituted in
anhydrous acetonitrile just prior to use (add a few pearls of 3-Å molecular sieves and wait
∼30 min before using the solution).
31P-NMR (CDCl3): δ 143.52 ppm.
1H-NMR (CDCl3): δ 1.09-1.20 (m, 12H-[C(H)(CH3)2]2), 1.35-1.50 (m, 2H, CH2), 1.56-
1.68 (m, 4H, CH2CH2), 1.70-1.83 (m, 2H, CH2), 2.61 (t, 2H, J = 6.34 Hz, CH2CN),
3.20-3.33 (m, 3H, CH2N + NH), 3.50-3.87 (m, 6H, CH2OP, (2 CH)), 3.97 (s, 3H, OCH3),
7.17-8.10 (m, 6H, Acr)
Couple the acridinyl phosphoramidite S.1c to 5′ end of oligodeoxyribonucleotide
chain
Automated coupling:
15a. When employing standard solid-phase DNA oligonucleotide synthesis cycles (1-
µmol scale) according to the classical phosphoramidite method, perform an addi-
tional detritylation step.
16a. Place a 0.1 M solution of the acridinyl phosphoramidite S.1c in anhydrous CH3CN
on the synthesizer. Carry out coupling by recycling a mixture of 0.1 mL of the
acridinyl phosphoramidite, 0.5 mL of 0.4 M 1H-tetrazole in anhydrous CH3CN, and
0.1 mL anhydrous CH3CN for 5 min. Repeat.
For synthesizers without a recycle program, perform a double coupling step. For optimal
coupling yields, changes in phosphoramidite concentration may be required depending on
the synthesizer used.
17a. Remove the excess phosphoramidite and tetrazole, and perform an iodine oxidation
reaction according to the standard procedure (UNIT 3.3, APPENDIX 3C).
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Manual coupling:
15b. When performing standard solid-phase oligodeoxyribonucleotide synthesis (1-
µmol scale) according to the classical phosphoramidite method, place the oligonu-
cleotide bound to the support in a short (4-mL) vial stoppered with a septum. Push
a needle through the septum and leave the vial in a desiccator containing P2O5 under
vacuum overnight.
The oligonucleotide must have a free 5′-hydroxy group.
16b. Fill the desiccator with nitrogen before opening it. With a syringe, add a mixture of
phosphoramidite S.1c (0.15 mL of a 0.15 M solution in anhydrous CH3CN) and
1H-tetrazole (0.5 mL of a 0.5 M solution in anhydrous CH3CN) to the support-linked
oligonucleotide. Leave the mixture for 10 min, shaking gently by hand from time
to time.
17b. Remove the excess reagents with a syringe and perform an oxidation reaction by
adding 1 mL of an aqueous iodine solution that is normally used on the synthesizer.
Remove the iodine solution after 1 min and wash the support extensively with
CH3CN.
Deprotect the acridine-oligodeoxyribonucleotide conjugates
18. Treat the support bearing the acridine-oligodeoxyribonucleotide conjugates with 5
mL of 0.4 M NaOH in 50:50 (v/v) MeOH/H2O at room temperature.
19. After 1 to 2 hr, remove the solid support by filtration. Wash it twice with 0.5 mL
water. Maintain the yellow solution at room temperature until deprotection is com-
plete.
The time required for oligonucleotide deprotection depends on the base composition of the
sequence and on the nature of the protective groups used to protect the nucleic bases.
Removal of the isobutyryl group from guanine residues requires ∼30 to 35 hr under these
conditions.
20. Neutralize the solution (containing the oligonucleotide conjugate S.1d) by adding
Dowex 50 ion-exchange resin until the pH of the solution reaches 6. Remove the resin
by filtration and wash it with water until the resin becomes pale yellow in color.
21. Concentrate the solution under vacuum to remove MeOH. Add ∼10 mL water, then
extract the aqueous solution three times with 3 mL ethyl acetate each time. Concen-
trate the aqueous solution to ∼3 to 4 mL.
22. Filter the solution through a 0.45-µm disposable filter to remove any particulates and
prevent the clogging of HPLC columns. Purify and characterize the oligonucleotide-
acridine conjugate (see Support Protocol).
SUPPORT
PROTOCOL
PURIFICATION AND CHARACTERIZATION OF
OLIGONUCLEOTIDE-ACRIDINE CONJUGATES
The following general procedure is applicable to the purification of 10- to 20-mer
oligodeoxyribonucleotides-acridine conjugates, assuming that the sequences under con-
sideration are not likely to form self-associated complexes such as G-tetrads. Should this
be the case, a specific purification procedure—not provided in this unit—must be used.
Purification can by improved by performing ion-exchange chromatography at pH 12
(Raynaud et al., 1996). Another solution to prevent the formation of G tetrads is to partially
replace 2’-deoxyguanosine with 7-deaza-2′deoxyguanosine (Raynaud et al., 1996). Gen-
erally, the crude oligodeoxyribonucleotide conjugates obtained from the protocol de-
scribed above are purified by ion-exchange chromatography. After a desalting step, the
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purity of the conjugates is verified on a reversed-phase column; in most cases this will
show that sufficient purity has been achieved. Alternatively, reversed-phase chromatog-
raphy allows easy purification of oligodeoxyribonucleotide-acridine conjugates when
acridine is bound to the 5′ end of oligonucleotides (making the conjugates more lipophilic
than the underivatized oligonucleotides). Sometimes the conjugate can be insufficiently
pure and a second purification is required. Usually it is performed using the system that
was not used for the first purification (i.e., a second purification step can be made using
reversed-phase after a first purification by ion-exchange chromatography and vice versa).
In all cases, oligodeoxyribonucleotide-acridine conjugates are detected during analysis
and purification by measuring UV absorption at 254 or 260 nm and at 425 nm (only the
acridine moiety of the conjugate absorbs light at that wavelength).
Materials
0.01 bis-Tris, pH 6 or 0.01 M NaH2PO4, pH 6.8 (APPENDIX 2A), each containing
10% or 10% HPLC-grade methanol (MeOH)
Sodium chloride (NaCl)
0.025 M Tris⋅Cl, pH 7 (APPENDIX 2A)
Acetonitrile (CH3CN)
1 M triethylammonium acetate (TEAA) buffer, pH 7 (stock solution; see recipe)
0.01 M Tris⋅Cl, pH 8 (APPENDIX 2A)
1 U snake venom phosphodiesterase (3′ exonuclease)
10 µg alkaline phosphatase
Ion-exchange columns: Mono Q HR 5/5 or HR 10/10 (Amersham Pharmacia
Biotech) or DEAE (Waters)
Reversed-phase columns: e.g., Lichrospher 100 RP 18 (5 µm, 125 × 4 mm, or 10
µm, 250 ×10 mm; Merck) or CC Nucleosil 100-5 C18 (125/4) column
(Macherey-Nagel)
Desalting columns: HR 10/10 columns (Amersham Pharmacia Biotech) packed
with Lichroprep RP 18 (Merck) or Sephadex G-10 or G-25 resin
1. Analyze the crude oligonucleotide-acridine conjugate solution via chromatography
by one of the following procedures, generally loading 10 to 20 µl of the crude solution
onto the column:
a. Ion-exchange chromatography with Mono Q HR 5/5 or HR 10/10 column: Use a
linear gradient of 0 to 100% 1 M NaCl in 0.01 M bis-Tris, pH 6, containing 10% or
20% MeOH, or 0 to 100% 1.5 M NaCl in 0.01 M NaH2PO4, pH 6.8, containing 10%
or 20% MeOH, with a flow rate of 1 mL/min (HR 5/5) or 4 mL/min (HR 10/10).
b. Ion-exchange chromatography with DEAE column (100 × 10 mm) : Use a linear
gradient of 0 to 100% 1.5 M NaCl in 0.025 M Tris⋅Cl, pH 7, containing 10%
MeOH, with a flow rate of 1 mL/min.
c. Reversed-phase chromatography with Lichrospher 100 RP 18 column (5 µm, 125
× 4 mm; or 10 µm, 250 × 10 mm): Use a linear gradient of CH3CN (5% to 80%)
in 0.1 M aqueous triethylammonium acetate, pH 7, with a flow rate of 1 mL/min
(5-µm column) or 4 mL/min (10-µm column).
d. Reversed-phase chromatography with CC Nucleosil 100-5 C18 (125/4) column:
Use a linear gradient of CH3CN (5% to 80%) in 0.1 M aqueous triethylammonium
acetate, pH 7, with a flow rate of 1 mL/min.
The gradients used must be chosen so as to afford the best separation. Usually an increasing
concentration of 1% of 1 M or 1.5 M NaCl per minute is used for ion-exchange chroma-
tography and an increasing concentration of ∼1% CH3CN per minute is used for reversed-
phase chromatography.
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2. Purify the remaining oligonucleotide-acridine conjugate by preparative reversed-
phase or ion-exchange chromatography column.
Use any type of column that was described in step 1, according to the recommended
conditions. Usually 1 mol of crude oligonucleotide-acridine conjugates can be purified
in two or three runs on Mono Q HR 10/10 column. On preparative reversed-phase columns,
reasonable purification can be achieved in a single run, but it is better to perform two.
Alternatively, purification can be achieved on analytical columns by performing five or
more runs.
3. Pool the fractions containing the conjugate and remove the organic solvents by
evaporation under reduced pressure.
4. If ion-exchange purification was used in step 2, desalt the conjugate using appropriate
desalting column. If reversed-phase purification was used, remove triethylam-
monium acetate by three consecutive lyophilizations. Resuspend the sample in 1 to
2 mL water between lyophilizations.
5. Analyze the oligonucleotide-acridine conjugate by ion-exchange chromatography
when the purification was performed by reversed-phase, or by reversed-phase when
the purification was achieved by ion-exchange, using the columns and parameters
described in step 1.
For example, analyze on a Lichrospher 100 RP 18 (5 m; 125 mm × 4 mm) column from
Merck using a linear gradient of CH3CN (5% to 35% over 40 min) in 0.1 M aqueous
triethylammonium acetate, pH 7, with a flow rate of 1 mL/min. Expected retention time is
28 min 18 sec for the acridine-oligonucleotide conjugate Acr(CH2)6pd5[T3C2T C2TCT].
After purification, UV spectra of oligodeoxyribonucleotide-acridine conjugates show
absorptions characteristic to the ligand. A typical spectrum of an oligonucleotide-acridine
conjugate is shown in Figure 4.3.4 (left). In addition, nuclease digestion of the conjugates
and reversed-phase HPLC analysis of the resulting monomers can be used to ascertain full
removal of the protective groups and base composition.
Figure 4.3.4 Absorption spectra of Acr(CH2)6pd[T3C2T C2TCT] (left) and Pso(CH2)6pd[T4 5-Me
C2T5-MeCT5-MeC3T5-MeCT] (right) recorded in water.
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6. Hydrolyze the oligonucleotide-acridine conjugate S.1d with nucleases by placing the
following in a 1.5-mL microcentrifuge tube:
∼1 OD unit conjugate S.1d in 10 µl H2O
50 µl 0.01 M Tris⋅Cl, pH 8
1 U snake venom phosphodiesterase
10 µg alkaline phosphatase.
Incubate 2 to 3 hr at 37°C.
7. Inactivate the enzyme by heating the mixture at 90°C for 2 min.
8. Analyse the hydrolysate by reversed-phase HPLC: e.g., using a Lichrospher 100 RP
18 column with a gradient of CH3CN (0% for 10 min, then 0 to 24% CH3CN over 30
min, then 24% to 56% CH3CN over 20 min) in 0.1 M aqueous triethylammonium
acetate, pH 7, with a flow rate of 1 mL/min.
These conditions permit the separation of natural nucleosides and a variety of modified
nucleosides. Identification can be made by comparison with authentic nucleosides. For
example: RtdC ≈ 5 min, Rt 5-MedC ≈ 10 min, RtT ≈ 13 min, RtdG ≈ 14 min 30 sec, RtdA ≈ 17
min 30 sec. Under these conditions the retention time of the acridine-linker derivative S.1b
is ∼51 min. Prolonged incubation at pH 8 induces degradation of S.1b.
Additional characterization can be made by MALDI and ESI mass spectrometry (UNITS
10.1 & 10.2). Acr(CH2)6pd[T3C2T C2TCT] has been characterized by MALDI-TOF using
2,4,6-trihydroxyacetophenone as matrix in the presence of diammonium L-tartrate. Quan-
tification of oligonucleotide-acridine conjugates can be made by using  = 8850 M−1 cm−1
at  = 425 nm (Asseline and Thuong, 1988). Usually when the synthesis is performed at
the micromole scale ∼15 to 20 OD units of pure oligonucleotide-acridine conjugate 15-mer
with mixed bases is obtained.
BASIC
PROTOCOL 2
DIRECT ADDITION OF PSORALEN DERIVATIVES TO THE 5′ END OF
OLIGODEOXYRIBONUCLEOTIDES
This strategy (illustrated in Figs. 4.3.1, 4.3.2, and 4.3.3) involves the attachment of a
hydroxylated linker to the psoralen ligand. Specifically, 5-methoxypsoralen S.2a is
demethylated to give the 5-hydroxypsoralen S.2b. The latter is reacted with 6-bromohex-
anol in the presence of K2CO3 (following a procedure adapted from that previously
reported by Kurfürst et al., 1993) to give the psoralen derivative S.2c. Phosphitylation of
S.2c affords S.2d (in another procedure adapted from the same reference). The phos-
phoramidite derivative S.2d is then condensed with the 5′-terminal hydroxyl of oligode-
oxyribonucleotides bound to solid supports. This conjugation is completed by the
deprotection, purification, and characterization of the psoralenyl-oligonucleotide conju-
gates S.2e.
Materials
5-Methoxypsoralen (S.2a)
Pyridine hydrochloride
CaCl2
Dichloromethane (CH2Cl2), distilled from P2O5 and passed over activated, basic
aluminum oxide
Methanol (MeOH), distilled
P2O5
N,N-Dimethylformamide, redistilled under vacuum over ninhydrin and stored over
4-Å molecular sieves
6-Bromo-1-hexanol
Potassium carbonate, anhydrous
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Ethyl acetate
Pyridine, anhydrous
N,N-Diisopropylethylamine (DIEA), distilled from KOH
Sodium sulfate, anhydrous
2-Cyanoethyl-N,N-diisopropylchlorophosphite
Triethylamine (Et3N)
10% (w/v) aqueous sodium carbonate (NaHCO3)
Cold saturated aqueous NaCl
Acetonitrile (CH3CN), DNA synthesis grade, anhydrous and stored over
3 Å-molecular sieves
Oligodeoxyribonucleotides bound to solid supports, such as controlled-pore glass
(CPG; UNIT 3.1), synthesized by classic phosphoramidite chemistry (1-µmol
scale)
DNA synthesis reagents recommended by synthesizer manufacturer
Concentrated (25%) aqueous ammonia
25-mL round-bottomed flask
Reflux condenser
Drying tube
Nitrogen gas
Oven
Analytical thin-layer chromatography (TLC) setup and silica-gel plates: e.g.,
Merck 5554 Kieselgel 60F plates, including UV lamp for detection 
Filter funnel, porosity 4
Desiccator
Argon
Silica gel for column chromatography: Merck 9387 Kieselgel 60 or Merck 7734
Kieselgel 60
Chromatographic columns: (3 cm × 50 cm) and (1.5 cm × 40 cm)
Prepare 5-(hydroxypsoralen), S.2b
1. Place 1 g (4.64 mmol) 5-(methoxypsoralen) S.2a and 4.27 g (37 mmol) pyridine
hydrochloride in a 25-mL round-bottomed flask equipped with a reflux condenser
and a calcium chloride drying tube, under a nitrogen atmosphere.
2. Verify that pyridine hydrochloride is at the bottom of the flask and heat the mixture
90 min at 180°C. Monitor the reaction by TLC using 90:10 (v/v) CH2Cl2/MeOH as
eluent.
The starting material S.2a (Rf = 0.9) will be transformed into S.2b (Rf = 0.50).
3. Allow the mixture to cool to room temperature. Solubilize the reaction mixture with
3 mL MeOH and slowly pour the solution in 50 mL cold water while stirring
magnetically to precipitate S.2b. Filter the solid over a filter funnel (porosity 4) and
dry it over P2O5 in a desiccator for 2 days. Analyze S.2b again by TLC.
The Rf value of S.2b is 0.50 when 90:10 (v/v) CH2Cl2/MeOH is used as eluent, and 0.65
when 50:50 (v/v) CH2Cl2/ethyl acetate is the eluent. Expected yield: 95% (885 mg, 4.38
mmol).
Characterize the product by appropriate analytical methods. Melting point: 280°C.
1H-NMR (DMSO-d6): δ 3.34 (br s, 1H), 6.23 (d, 1H, J = 9.7 Hz, C3 Pso), 7.14 (S, 1H, C8
Pso), 7.18 (d, 1H, J = 2.2 Hz, C4’ Pso), 7.89 (d, 1H, J = 2.3 Hz, C5’ Pso), 8.23 (d, 1H, J =
9.5 Hz, C4 Pso).
Mass analysis. I.S. polarity positive. Calculated for C11H6O4: M+H=203.0. Found 203.0.
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Prepare 5-(6-hydroxyhexyloxy)-psoralen, S.2c
4. Place a solution of 5-hydroxypsoralen S.2b (0.6 g, 2.97 mmol) in 10 mL anhydrous
N,N-dimethylformamide in a 25-mL round-bottomed flask equipped with a reflux
condenser and a calcium chloride drying tube. Add successively 1.16 mL 6-bromo-
1-hexanol (1.61 g, 8.91 mmol) and 0.61 g anhydrous potassium carbonate (4.45 mmol).
5. Heat the flask at 65°C in the dark under an argon atmosphere and stir for 4 hr.
6. Allow the mixture to cool to room temperature and remove insoluble salts by
filtration, then concentrate the filtrate to dryness under reduced pressure.
7. Purify the residue (2.5 g) on a silica-gel column (3 cm ×  50 cm, 70 g silica) using
increasing concentrations of MeOH in CH2Cl2 (1:100 to 3:97, v/v):
200 mL of 1% MeOH in CH2Cl2;
200 mL of 2% MeOH in CH2Cl2;
200 mL of 2.5% MeOH in CH2Cl2;
and 200 mL of 3% MeOH in CH2Cl2.
8. Monitor the fractions by silica-gel TLC using 90:10 (v/v) CH2Cl2/MeOH or 50:50
(v/v) CH2Cl2/ethyl acetate as eluent. Collect the fractions containing the pure product
and remove the solvent under reduced pressure.
The Rf value of  S.2c is 0.43 when 90:10 (v/v) CH2Cl2/MeOH is the eluent, and 0.45 when
50:50 (v/v) CH2Cl2/ethyl acetate is the eluent.
Expected yield: 75% (672 mg, 2.22 mmol). Melting point: 100°C. 
1H-NMR (CDCl3):  1.38-1.60 (m, 6H), 1.82-1.95 (, 2Η, ΧΗ2), 3.60-3.71 (m, 2H,
CH2OH), 4.45 (t, 2H, J = 6.4 Hz, -CH2OAr), 6.27 (d, 1H, J = 9.7 Hz, C3 Pso), 6.94 (d, 1H,
J = 2.3 Hz, C4’ Pso), 7.26 (s, 1H, C8), 7.58 (d, 1H, J = 2.4 Hz, C5’ Pso), 8.15 (d, 1H, J =
9.5 Hz, C4 Pso)
Mass analysis. I.S. polarity positive. Calculated for C17H18O5: M+H=303.0. Found 303.0.
Prepare [5-(ω-hexyloxy)-psoralenyl]-(2-cyanoethyl)-N,N-diisopropyl-
phosphoramidite S.2d
9. Place 0.30 g 5-(6-hydroxyhexyloxy)-psoralen (1 mmol; S.2c) in a 25-mL round-bot-
tomed flask, dry it by coevaporation with anhydrous pyridine and leave under vacuum
for at least 12 hr.
See Basic Protocol 1, steps 7, 8 and 9, for procedure.
10. Under a nitrogen atmosphere and magnetic stirring at room temperature add using a
syringe 6 mL dichloromethane, 0.35 mL DIEA (0.258 g, 2 mmol) and then dropwise
0.29 mL 2-cyanoethyl-N,N-diisopropylchlorophosphite (0.307 mg, 3 mmol). Leave
20 min at room temperature. Monitor the reaction by silica-gel TLC using 95:5 (v/v)
ethyl acetate/Et3N as eluent. Pre-elute the TLC plate with eluent before spotting the
samples.
11. Shake the solution twice with 2 mL of 10% (w/v) aqueous Na2CO3 and once with 2
mL of a cold saturated aqueous NaCl solution. Dry the organic layer over anhydrous
sodium sulfate and concentrate it to dryness.
12. Purify the residue (500 mg) on a silica-gel column (1.5 cm × 40 cm, 20 g silica) using
95:5 (v/v) ethyl acetate/Et3N as eluent. Monitor the fractions by silica-gel TLC using
95:5 (v/v) ethyl acetate/Et3N as eluent.
The Rf value of S.2d is 0.87.
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13. Pool the fractions containing the pure product. Remove the solvents under reduced
pressure and coevaporate with anhydrous CH3CN.
Expected yield: 65% (326 mg, 0.65 mmol) of a colorless oil. Purified psoralenyl phos-
phoramidite S.2d can be stored at −20°C for a few months and should be reconstituted in
anhydrous acetonitrile just prior to use (add a few pearls of 3-Å molecular sieves and wait
∼30 min before using the solution).
31P-NMR (CDCl3):  149.47 ppm
1H-NMR (CDCl3):  1.12-1.23 (m, 12H -[C(H)(CH3)2]2), 1.38-1.70 (m, 6H, (CH2)3),
1.82-1.85 (m, 2H, CH2), 2.60 (t, 2H, J = 6. Hz, CH2CN), 3.52-3.73 (m, 4H, CH2O, [C(H)]2),
3.74-3.90 (m, 2H, CH2OP), 4.45 (t, 2H, J = 6.33 Hz, -CH2OAr), 6.27 (d, 1H, J = 9.8 Hz,
C3 Pso), 6.94 (d, 1H, J = 2 Hz, C4’ Pso), 7.13 (s, 1H, C8), 7.58 (d, 1H, J = 2.3 Hz, C5’ Pso),
8.15 (d, 1H, J = 9.8 Hz, C4 Pso).
Couple the psoralenylphosphoramidite S.2d to the 5′-end of oligodeoxyribonu-
cleotides
Automated coupling:
14a. After standard solid-phase DNA oligonucleotide synthesis (1-µmol scale) according
to the classical phosphoramide method, perform an additional detritylation step.
15a. Place a 0.1 M solution of the psoralenyl phosphoramidite S.2d in anhydrous CH3CN
on the synthesizer. Carry out coupling by recycling a mixture of 0.1 mL of the
psoralenyl phosphoramidite, 0.5 mL of 0.4 M 1H-tetrazole in anhydrous CH3CN,
and 0.1 mL anhydrous CH3CN for 5 min. Repeat.
For synthesizers without a “recycle” program, perform a double coupling step. For optimal
coupling yields changes in amidite concentration may be required, depending on the
synthesizers used.
16a. Remove the excess phosphoramidite and tetrazole, and perform an aqueous iodine
oxidation reaction according to the standard procedure.
Manual coupling:
14b. When performing standard solid-phase oligodeoxyribonucleotide synthesis (1-
µmol scale) according to the classical phosphoramidite method, place the oligonu-
cleotide bound to the support in a short (4-mL) vial stoppered with a septum. Push
a needle through the septum and leave the vial in a desiccator containing P2O5 under
vacuum overnight.
The oligonucleotide must have a 5′-hydroxy group.
15b. Fill the desiccator with nitrogen before opening it. Using a syringe, add a mixture
of phosphoramidite S.2d (0.15 mL of a 0.15 M solution in anhydrous CH3CN) and
1H-tetrazole (0.5 mL of a 0.5 M solution in anhydrous CH3CN) to the support-linked
oligonucleotide. Leave the mixture at room temperature for 10 min, shaking gently
by hand from time to time.
16b. Remove the excess reagents with a syringe and perform an oxidation reaction by
adding 1 mL iodine solution that is normally used on the synthesizer. Remove the
iodine solution after 1 min and wash the support extensively with CH3CN.
Deprotect oligodeoxyribonucleotide-psoralen conjugates
17. Add 5 mL concentrated 25% aqueous ammonia to a vial containing the psoralen-oli-
godeoxyribonucleotide conjugate bound to the support and leave it 1 hr at 55°C.
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18. Discard the support and leave the ammonium hydroxide solution an additional 6 hr
at 55°C.
19. Evaporate the ammoniacal solution to dryness.
20. Solubilize the crude material S.2e with 12 mL water and extract three times with 3
mL ethyl acetate each time. Reduce the volume of the solution to ∼3 to 4 mL under
reduced pressure.
21. Purify and characterize the oligodeoxyribonucleotide-psoralen conjugates (see Basic
Protocol 1; the conjugates can be detected at 260 and 320 nm).
For example analysis performed on a Lichrospher 100 RP 18 (5 m; 125 mm × 4 mm)
column using a linear gradient of CH3CN (5% to 35% over 40 min) in 0.1 M aqueous
triethylammonium acetate, pH 7, at a flow rate of 1 mL/min indicates a retention time of
30 min 16 sec for the psoralen-oligonucleotide conjugate Pso(CH2)6pd[T45-MeC2T5-Me-
CT5-MeC3T5-MeCT].
As for oligonucleotide-acridine conjugates, base composition can be verified by nuclease
degradation (same protocol). In this case reversed-phase analysis of hydrolysates per-
formed under the conditions described for the oligonucleotide-acridine conjugates indi-
cates a retention time of 53 min 36 sec for S.2c. Quantification of oligonucleotide- psoralen
conjugates can be made by using  ≈ 10 000 M−1 cm−1 at  = 320 nm (unpub. observ.).
When the synthesis is performed at the micromole scale, ∼15 to 20 OD units of pure
oligonucleotide-psoralen conjugates 15-mer with mixed bases are obtained. The absorp-
tion spectrum of the psoralen-oligonucleotide conjugate Pso(CH2)6pd[T45-MeC2T5-Me-
C T5-MeC3T5-MeCT] is represented in Figure 4.3.4 (right).
REAGENTS AND SOLUTIONS
1M triethylammonium acetate (TEAA) buffer, pH 7 (stock solution) 
In a fume hood, add successively to a 1 liter beaker (equipped with a stirring bar)
distilled water (810 mL), triethylamine (134 mL) and glacial acetic acid (57 mL).
Mix thoroughly and adjust to pH 7 by adding either a few drops of triethylamine or
a few drops of glacial acetic acid. 
COMMENTARY
Background Information
Two strategies can be used to attach ligands
to the 5′ end of oligodeoxyribonucleotides.
This unit describes one of these strategies,
which involves the direct addition of a ligand
to the 5′ end of an oligodeoxynucleotide during
its initial synthesis via the phosphoramidite
approach. Although methods have been devel-
oped for derivatizing the 5′ terminus of oligode-
oxyribonucleotides in homogenous solution
(Thuong et al., 1984, 1987; Asseline and
Thuong, 1984; Asseline et al., 1988), only con-
jugation reactions on solid supports are re-
ported in this unit (Thuong and Chassignol
1988, Dupret et al., 1994; Asseline et al., 1996).
This strategy is applicable when the ligand is
available in sufficient amounts, and its solubil-
ity and chemical stability are compatible with
the conditions required for the preparation of
its phosphoramidite or H-phosphonate deriva-
tives. In addition, the ligand should be stable
under the conditions required for the coupling
reaction and to those conditions used for com-
plete deprotection of the oligodeoxynucleotide
chain and its release from the support.
The second strategy, not covered here, in-
volves the incorporation of appropriate func-
tional groups into two unprotected reactants.
The coupling of these functionalized reactants
results in the formation of oligodeoxyribonu-
cleotide conjugates. Various oligodeoxyri-
bonucleotide conjugates can be prepared using
this strategy from only one oligodeoxyribonu-
cleotide synthesis, provided that the required
amount for each conjugate is low.
Future units will describe the coupling of a
number of ligands (intercalators, photoreactive
and cleavage reagents, and labels) to oligode-
oxyribonucleotides post-synthetically. These
ligands are typically 2-methoxy-6-choro-9-
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aminoacridine as an intercalator, psoralen as a
photo-cross-linking reagent, and phenan-
throline-Cu as a cleavage reagent. More re-
cently, the authors have used thiazole orange as
a reporter group. This strategy involves the
incorporation of linkers carrying suitable func-
tional groups into ligands and the addition of
amino, phosphorothioate, phosphate, or sulfhy-
dryl functions to the 5′ end of oligonucleotides,
as well as coupling methods for linking both
entities.
Alternatively, many reporter groups bearing
functional groups that will react with 5′-thiol,
5′-terminal phosphorothioate, and 5′-amino
groups are available from commercial sources.
Heterobifunctional reagents, which allow reac-
tion with a thiol function and with the primary
amino function of various ligands, are also
available commercially. These reagents, listed
in UNIT 4.2, are very useful when there is no need
for conjugates to have a well-defined linker
between the oligodeoxyribonucleotide and the
ligand.
The coupling methods developed in this unit
and future units can be used to prepare oligode-
oxyribonucleotide conjugates composed of
natural β-deoxyribonucleosides (Thuong and
Chassignol 1988, Dupret et al., 1994, Asseline
et al., 1996), unnatural α-D-deoxyribonu-
cleosides (Kurfürst et al., 1993), or 2′-O-
methylribonucleosides (unpub. observ.). When
the chain assembly is performed in the usual
(3′→5′) orientation, the modifying steps (i.e.,
direct incorporation of the ligand or the masked
5′-terminal functional group) are carried out at
the end of the chain assembly just prior to the
deprotection step. Given that oligodeoxyri-
bonucleotides can be purchased fully protected
and bound to the support, 5′-end modification
can be performed manually.
Procedures reported in this unit may be used
to prepare oligodeoxyribonucleotides cova-
lently linked via their 5′ end to molecules such
as intercalating agents, and other reactive com-
pounds the properties of which are described in
UNIT 4.2. In many examples, oligodeoxyribonu-
cleotide conjugates properties, such as strong
complex stabilization when the ligand is an
intercalator (Asseline et al., 1984, 1996, Sun et
al., 1989; Giovannangeli et al., 1996) or best
cleavage or cross-linking efficiency when the
ligand is a reactive group, are largely dependent
on the geometry of the complex formed be-
tween the ligand and its target (Takasugi et al.,
1991; Giovannangeli et al., 1992; Costes et al.,
1993, Grigoriev et al., 1993). Using these pro-
cedures linkage parameters between the oli-
godeoxyribonucleotide and the ligand, such as
the size and nature of the linker connecting the
two entities, may be varied to prepare oligode-
oxyribonucleotide-ligand conjugates exhibit-
ing optimal properties for specific experimental
needs.
Critical Parameters and
Troubleshooting
In the case of acridine-containing oligode-
oxyribonucleotides, the use of ammonia for the
deprotection step must be avoided since it in-
duces cleavage of the C9-N bond between the
acridine and the linker. Therefore, a 0.4 N
sodium hydroxide solution in 50:50 (v/v)
H2O/MeOH is recommended. It is also recom-
mended that the oligonucleotide-acridine con-
jugate solutions be stored between pH 6 and 7.
Storage at pH values between 7 and 9 leads to
considerable degradation. Protection of flasks
and columns from light during the different
steps of these protocols is recommended be-
cause acridine and psoralen derivatives are
light-sensitive. In any case, purification steps
must be as short as possible. It is always possi-
ble that the conditions required for deprotection
of the conjugates may be incompatible with the
stability of some modified nucleoside incorpo-
rated into the sequence of interest. To avoid
obtaining a low yield of oligonucleotide-ligand
conjugates, it is possible to deprotect an aliquot
of the conjugates to verify the coupling effi-
ciency of the amidite derivatives. If the cou-
pling efficiency is insufficient, it is possible to
perform additional coupling of the ligand. At
the micromole scale it is usual to obtain about
20 OD units of pure conjugates when working
with mixed DNA sequences. In some cases,
when working with oligonucleotides contain-
ing sequences, inducing self associated struc-
ture, the purification step can be particularly
challenging. In such cases, it is advisable to
purify the acridine-oligonucleotide conjugates
on a Mono-Q column at pH 12. In the case of
sequences containing stretches of dG, the better
way to solve the problem is to partially replace
the dGs with 7-deaza-2′-deoxyguanosines
(Raynaud et al., 1996).
Anticipated Results
 The yields reported for the various steps can
be different when the syntheses are performed
at scales other than those described. Using the
protocols provided here and starting with 300
mg of the acridine-linker derivative S.1b, 300
mg of the purified acridine phosphoramidite
S.1c can be obtained. This can be used to
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synthesize acridine-oligodeoxyribonucleotide
conjugates S.1d. Usually 15 to 20 OD units of
purified conjugates S.1d can be expected when
the synthesis is performed at the µmol scale. 
In the case of the psoralen derivatives, start-
ing with 310 mg of the psoralen-linker deriva-
tive S.2c it is possible to obtain 325 mg of the
purified psoralen phosphoramidite derivative
S.2d. The latter is then used to prepare psoralen-
oligodeoxyribonucleotide conjugates S.2e.
When DNA synthesis is performed at the µmol
scale, the yields obtained for conjugates S.2e
(15 to 20 OD units) are similar to those obtained
for the preparation of the conjugates S.1d.
Time Considerations
Providing all reagents and materials re-
quired for each step are available, most of the
reactions are simple and rapid. Preparation of
compounds S.1b and S.2b requires 3 days in-
cluding the drying step, while only two days
are necessary to obtain compound S.2c.  The
time required for the preparation of phos-
phoramidite derivatives S.1c or S.2d is one day
provided that the ligand-linker derivatives
have been dried the previous day and left
under vacuum in a desiccator overnight. Oli-
gonucleotides chain assemblies and the addi-
tion of the ligand to the 5′-end of the oligonu-
cleotide can be performed the same day when
the ligand is added directly with the synthesizer.
Otherwise the manual coupling requires leav-
ing the support bearing the oligonucleotide
under vacuum overnight. The deprotection step
for psoralen-oligodeoxyribonucleotide conju-
gates S.2e takes a few hours while the duration
of the deprotection step for acridine-oligode-
oxyribonucleotide conjugates S.1d can be ex-
tended to almost two days. The time required
for the purification of the ligand-oligonu-
cleotide conjugates S.1d and S.2e can vary
depending on the sequences. When two succes-
sive purification steps are necessary the time
can be from five to ten days including rounds
of lyophilization (overnight) or desalting and
additional analyses. Characterization of the pu-
rified conjugates S.1d and S.2e can be achieved
in three or four days.
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